Canada’s strategy for becoming a global leader in biotechnology is about to receive a major endorsement with the imminent decision by DSM Biologics to double its Montreal bioprocessing facility. Although the deal isn’t final, construction crews are already preparing the site on land leased from its neighbour, the National Research Council’s Biotechnology Research Institute.